We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
+7.8%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$38.8B
AUM Growth
+$2.96B
(+8.3%)
Cap. Flow
+$1.14B
Cap. Flow
% of AUM
2.93%
Top 10 Holdings %
Top 10 Hldgs %
12.28%
Holding
2,861
New
368
Increased
965
Reduced
1,202
Closed
293
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$401M |
| 2 |
Netflix
NFLX
|
+$388M |
| 3 |
Ford
F
|
+$340M |
| 4 |
SCHW
Charles Schwab
SCHW
|
+$330M |
| 5 |
Boeing
BA
|
+$329M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$391M |
| 2 |
TSMC
TSM
|
+$387M |
| 3 |
Oracle
ORCL
|
+$282M |
| 4 |
Advanced Micro Devices
AMD
|
+$248M |
| 5 |
Microsoft
MSFT
|
+$247M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.93% |
| 2 | Healthcare | 17.44% |
| 3 | Industrials | 12.95% |
| 4 | Consumer Discretionary | 11.52% |
| 5 | Financials | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Perspective Therapeutics
CATX
$327M
| $26.7K | ﹤0.01% |
4,180
-270
| -6% | -$1.1K |
|
2502
Aquestive Therapeutics
AQST
$472M
| $26.3K | ﹤0.01% |
23,100
-9,300
| -29% | -$8.06K |
|
|
ONCR
2503
DELISTED
Oncorus, Inc.
ONCR
| $26.1K | ﹤0.01% |
75,712
-23,488
| -24% | -$8.77K |
|
|
CWBR
2504
DELISTED
CohBar, Inc. Common Stock
CWBR
| $25.9K | ﹤0.01% |
14,465
-2,200
| -13% | -$4.44K |
|
2505
Blend Labs
BLND
$433M
| $25.5K | ﹤0.01% |
25,600
+8,200
| +47% | +$12.6K |
|
2506
Clover Health Investments
CLOV
$2.28B
| $25.4K | ﹤0.01% |
+30,000
| New | +$32.8K |
|
|
AUTL
2507
Autolus Therapeutics
AUTL
$386M
| $25.2K | ﹤0.01% |
+13,700
| New | +$26.8K |
|
|
VIRX
2508
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $25K | ﹤0.01% |
15,719
-25,300
| -62% | -$46K |
|
|
SURF
2509
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $24.3K | ﹤0.01% |
34,800
| – | – |
|
|
PVLA
2510
Palvella Therapeutics
PVLA
$2.05B
| $22.8K | ﹤0.01% |
293
-556
| -65% | -$64.4K |
|
2511
Energous
WATT
$72.8M
| $21.8K | ﹤0.01% |
67
| – | – |
|
2512
Fortress Biotech
FBIO
$113M
| $21.2K | ﹤0.01% |
1,727
-120
| -6% | -$1.43K |
|
2513
Twin Vee PowerCats
VEEE
$8.51M
| $20.8K | ﹤0.01% |
+33
| New | +$24.2K |
|
2514
Castor Maritime
CTRM
$18.3M
| $20.8K | ﹤0.01% |
2,630
-80
| -3% | -$881 |
|
2515
LifeMD
LFMD
$186M
| $20.4K | ﹤0.01% |
12,000
-3,700
| -24% | -$6.53K |
|
|
HEPA
2516
DELISTED
Hepion Pharmaceuticals
HEPA
| $20.1K | ﹤0.01% |
26
| – | – |
|
2517
Mustang Bio
MBIO
$4.78M
| $19.9K | ﹤0.01% |
72
-4
| -5% | -$1.64K |
|
2518
CuriosityStream
CURI
$145M
| $19.6K | ﹤0.01% |
14,500
-4,200
| -22% | -$6.66K |
|
2519
Traws Pharma
TRAW
$7.81M
| $19.5K | ﹤0.01% |
1,070
-936
| -47% | -$20.3K |
|
|
TCON
2520
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $19.5K | ﹤0.01% |
515
-2,145
| -81% | -$70.3K |
|
|
YSG
2521
Yatsen Holding
YSG
$322M
| $19.2K | ﹤0.01% |
+2,600
| New | +$19.6K |
|
|
LCI
2522
DELISTED
Lannett Company, Inc.
LCI
| $18.9K | ﹤0.01% |
10,850
-45,500
| -81% | -$100K |
|
|
CMMB
2523
Chemomab Therapeutics
CMMB
$10.5M
| $18.8K | ﹤0.01% |
+2,950
| New | +$23.1K |
|
|
CRGE
2524
DELISTED
Charge Enterprises, Inc. Common Stock
CRGE
| $18.4K | ﹤0.01% |
16,700
-500
| -3% | -$630 |
|
2525
Absci
ABSI
$1.21B
| $17.9K | ﹤0.01% |
10,200
-500
| -5% | -$1.21K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q1 2023 Portfolio in Review
As of Q1 2023, Two Sigma Advisers held 2,861 positions worth $38.8B, up 8.3% from $35.8B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Two Sigma Advisers's Q1 2023 filing shows 368 new, 965 increased, 1,202 reduced and 293 closed positions. Its largest new stake was Netflix: 11,730,000 shares worth $405M. The largest sale was Tesla, an estimated $391M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 25% a quarter earlier, followed by Healthcare and Industrials.
- Two Sigma Advisers's largest Q1 2023 buy was Netflix: 11,730,000 shares worth $405M.
- Two Sigma Advisers added most to CVS Health in Q1 2023, an estimated $401M increase.
- Two Sigma Advisers's biggest Q1 2023 reduction was TSMC, cutting an estimated $387M.
- Two Sigma Advisers fully exited Tesla in Q1 2023, selling an estimated $391M.
- Two Sigma Advisers's ten largest holdings make up 12% of its $38.8B portfolio in Q1 2023.
- Two Sigma Advisers opened 368 new positions and closed 293 in Q1 2023.
- Two Sigma Advisers's portfolio value rose 8.3% quarter-over-quarter to $38.8B.
Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.